UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.559-566

2016

Volltextzugriff (PDF)

Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems

The Journal of pharmacology and experimental therapeutics, 2006-02, Vol.316 (2), p.762-771

2006

Volltextzugriff (PDF)

Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism

Drug metabolism and disposition, 2006-07, Vol.34 (7), p.1175-1181

2006

Volltextzugriff (PDF)

Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys

The Journal of pharmacology and experimental therapeutics, 2009-04, Vol.329 (1), p.102-111

2009

Volltextzugriff (PDF)

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

The New England journal of medicine, 2014-03, Vol.370 (13), p.1189-1197

2014

Volltextzugriff (PDF)

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Volltextzugriff (PDF)

Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay

The Journal of pharmacology and experimental therapeutics, 2004-03, Vol.308 (3), p.1040-1045

2004

Volltextzugriff (PDF)

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.392-403

2020

Volltextzugriff (PDF)

Predation by Red Foxes (Vulpes vulpes) at an Outdoor Piggery

Animals (Basel), 2016-10, Vol.6 (10), p.60-60

2016

Volltextzugriff (PDF)

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

American journal of physiology: endocrinology and metabolism, 2009-11, Vol.297 (5), p.E1105-E1114

2009

Volltextzugriff (PDF)

Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

Cancer chemotherapy and pharmacology, 2019-09, Vol.84 (3), p.501-511

2019

Volltextzugriff (PDF)

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.240-246

2020

Volltextzugriff (PDF)

Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Journal of clinical pharmacology, 2017-05, Vol.57 (5), p.652-662

2017

Volltextzugriff (PDF)

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Cancer chemotherapy and pharmacology, 2021-04, Vol.87 (4), p.475-486

2021

Volltextzugriff (PDF)

Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies

Analytical and bioanalytical chemistry, 2014-11, Vol.406 (28), p.7389-7396

2014

Volltextzugriff (PDF)

Diagnostic capability of low- versus high-field magnetic resonance imaging for lumbar degenerative disease

Spine (Philadelphia, Pa. 1976), 2015-03, Vol.40 (6), p.382-391

2015

Volltextzugriff (PDF)

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2017-06, Vol.79 (6), p.1119-1128

2017

Volltextzugriff (PDF)

Development of an individualized procedure to induce reward-related impulsivity and evaluating its impact on drinking control

Addictive behaviors, 2022-10, Vol.133, p.107378-107378, Article 107378

2022

Volltextzugriff (PDF)

Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis

Journal of clinical pharmacology, 2012-08, Vol.52 (8), p.1150-1161

2012

Volltextzugriff (PDF)

Intraosseous Glomus Tumor Treated by Toe-to-Finger Transfer: Case Report

The Journal of hand surgery (American ed.), 2009-04, Vol.34 (4), p.710-714

2009

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice

The AAPS journal, 2009-12, Vol.11 (4), p.700-709

2009

Volltextzugriff (PDF)

Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14509-e14509

2023

Volltextzugriff (PDF)

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11512-11512

2022

Volltextzugriff (PDF)

Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.511-511

2020

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(77)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(57)
Humans
(41)
Female
(29)
Adult
(25)
Male
(19)
Middle Aged
(16)
Biological And Medical Sciences
(15)
Oncology
(15)
Medical Sciences
(13)
Pharmacology & Pharmacy
(12)
Pregnancy
(10)
Aged
(9)
Animals
(9)
Patients
(9)
Ceritinib
(8)
Pharmacokinetics
(7)
Aged, 80 And Over
(6)
Anaplastic Lymphoma Kinase
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems

Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism

Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Predation by Red Foxes (Vulpes vulpes) at an Outdoor Piggery

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6

Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies

Diagnostic capability of low- versus high-field magnetic resonance imaging for lumbar degenerative disease

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

Development of an individualized procedure to induce reward-related impulsivity and evaluating its impact on drinking control

Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis

Intraosseous Glomus Tumor Treated by Toe-to-Finger Transfer: Case Report

Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice

Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST)

Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations

Suchergebnisse filtern